Email Updates

Place quotation marks around exact phrases (e.g. "new york"). Note: Trial names have a space before the number (e.g. HVTN 100).

You are here

Home

Trial Search

Trial Name Prevention Option Phase Start Date Sponsors Countries Population Candidate(s) Status
IAVI G002 HIV Vaccine I August 2021 International AIDS Vaccine Initiative; ModernaTX, Inc.; The University of Texas at San Antonio; George Washington University; Fred Hutchinson Cancer Research Center; Emory University Men, Women Ongoing
HVTN 706/ HPX3002 Mosaico HIV Vaccine III October 2019 Janssen Vaccines & Prevention B.V. United States of America, Argentina, Italy, Mexico, Peru, Poland, Spain Men Ad26.Mos4.HIV, gp140 Ongoing
PV1/PrEPVacc HIV Vaccine, PrEP IIb January 2020 Sponsor: Imperial College London. Coordinating partners: P Kaleebu, E Ruzagira (MRC/UVRI & LSHTM, Uganda); J Weber/J Fox/C Kingsley (Imperial College, UK); S McCormack (UCL, UK); K Chinyenze (IAVI-Kenya); G Pantaleo/S Ding (CHUV/EVF, Switzerland) Uganda, South Africa, United Republic of Tanzania, Mozambique Men, Women DNA , MVA, Protein Ongoing
HVTN 124/ PDPHV-201401 HIV Vaccine I March 2018 NIAID (DAIDS-ES: 38302) United States of America Men, Women gp120 (A,B,C,A/E)/GLA-SE, env (A,B,C,A/E)/gag (C)/GLA-SE Ongoing
HVTN 122/gp145 C.6980 HIV Vaccine I December 2017 NIAID (DAIDS-ES: 12030) United States of America Men, Women gp145 C.6980 Ongoing
HVTN 115/ EnvSeq-1 and CH505 HIV Vaccine I August 2017 NIAID (DAIDS-ES: 12042) United States of America Men, Women CH505TF Ongoing
HVTN 118/ HPX 2003/ IPCAVD 012/ ASCENT HIV Vaccine I/II March 2017 Janssen, HVTNNIAID, MHRP, BIDMC, Ragon United States of America, Kenya, Rwanda Men, Women Ad26.Mos.HIV, gp140 Ongoing
HVTN 117/ HPX2004/ IPCAVD011/ TRAVERSE HIV Vaccine I/II July 2016 National Institutes of Health, Henry M Jackson Foundation for Advancement of Military Medicine and the US Department of Defense, Ragon Institute of MGH, MIT, & Harvard, Bill & Melinda Gates Foundation, and Janssen Vaccines & Prevention United States of America, Rwanda Men, Women Ad26.Mos.HIV, gp140 Ongoing
RV328/ AIDSVAX HIV Vaccine II July 2014 U.S. Army Medical Research and Materiel Command, NIH Thailand Men, Women AIDSVAX Ongoing
HVTN 110 HIV Vaccine I March 2015 Emergent BioSolutions, NIAID United States of America Men, Women Ad4, AIDSVAX, gp120 Ongoing
HVTN 107/ ALVAC-HIV (vCP2438) HIV Vaccine I/II July 2017 NIAID South Africa, Mozambique, Zimbabwe Men, Women ALVAC, gp120 Ongoing
HVTN 702 HIV Vaccine III, IIb October 2016 NIAID, Bill and Melinda Gates Foundation, GlaxoSmithKline, Sanofi South Africa Men, Women ALVAC, gp120 Ongoing
HIV-V-A004/ IPCAVD 009 (APPROACH) HIV Vaccine I/II December 2014 Crucell Holland BV; Collaborators include: US National Institute of Allergy and Infectious Diseases Division of AIDS (US NIAID); US Military HIV Research Program (US MHRP); Beth Israel Deaconess Medical Center; International AIDS Vaccine Initiative (IAVI) United States of America, Rwanda, South Africa, Thailand, Uganda Men, Women Ad26.Mos.HIV, gp140, MVA Ongoing
RV 306 HIV Vaccine II September 2013 US Army Medical Research and Materiel Command; National Institute of Allergy and Infectious Diseases (NIAID) Thailand Men, Women AIDSVAX, ALVAC Ongoing
RV 305 HIV Vaccine II April 2012 US Army Medical Research and Materiel Command; National Institutes of Health (NIH) Thailand Men, Women AIDSVAX, ALVAC Ongoing
CSVDoc